Abstract
#Bisphosphonates (BPs), #antiresorptive and #antiangiogenicdrugs are
used to prevent metastatic bone cancers and to treat osteoporosis
and Paget’s disease. Besides BPs, due to the growing number of
#osteonecrosis cases associated with other antiresorptive and
antiangiogenic
therapies, American Association of Oral and #MaxillofacialSurgeons
(AAOMS) recommends changing the terminology of bisphosphonate
related osteonecrosis of the jaws (BRONJ) and favors the term medication
related osteonecrosis of the jaws (MRONJ) in 2014. The aim of this
article was to report to case of a 79-year-old male with using oral
ibandronate with osteonecrosis in the left retromolar area of the
mandible.
The therapeutic approach consisted of debridement of te osteonecrotic
area and using leucocyte-rich and #platelet-richfibrin (L-PRF) for the
treatment of medication-related osteonecrosis of the jaw (MRONJ).
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.